Month: 2024-10

深圳, 2024年10月18日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司（「康哲藥業」）欣然宣佈，磷酸蘆可替尼乳膏（「蘆可替尼乳膏」或「產品」）在中山陳星海中西醫結合醫院、佛山複星禪誠醫院、以及東莞松山湖東華醫院為符合條件的白癜風患者開出大灣區首批處方。產品於2024年4月11日獲得澳門政府藥物監督管理局（ISAF）批准新藥上市申請，隨後通過「港澳藥械通」政策，並於8月19日獲得廣東省藥品監督管理局批准，正式落地粵港澳大灣區內地指定醫療機構，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的治療，為相關適應症患者提供了全新治療選擇。此外，蘆可替尼乳膏白癜風適應症新藥上市許可申請已於9月24日獲得中國國家藥品監督管理局（NMPA）受理。根據海南博鰲樂城國際醫療旅遊先行區藥品真實世界數據應用試點程式有關規定，蘆可替尼乳膏在中國開展真實世界研究，療效積極，與境外關鍵臨床研究結果一致。所有的次要療效指標均顯示出與主要療效指標一致的獲益趨勢，且治療時間越長，患者的白癜風治療效果持續改善。同時利用了樂城先行區安全監測數據，未發現新的安全性事件。不良反應的嚴重程度大部分均為1級或2級，未發生導致停藥或退出的不良事件（AE），未發生研究藥物相關的嚴重不良事件（SAE）。若產品於中國大陸獲批上市，其有望成為首個經NMPA批准用於白癜風複色的處方藥，將為中國廣大白癜風患者帶來治療新曙光。除上述進展外，產品此前於2023年8月12日獲得海南省藥監局批準臨床急需進口，並於8月18日正式落地海南博鰲樂城國際醫療旅遊先行區，用於12歲及以上青少年和成人患者伴面部受累的非節段型白癜風的局部治療。受益于國家賦予海南自由貿易港、博鰲樂城國際醫療旅遊先行區「先行先試」特許政策，中國白癜風患者可在博鰲超級醫院先行申請使用產品並接受專家團隊的治療。截至2024年6月30日，已有超3,200例患者在博鰲超級醫院使用蘆可替尼乳膏進行治療。康哲藥業始終以患者為中心，以臨床需求驅動創新，為提升藥物可及性而持續努力。本次蘆可替尼乳膏得益於「港澳藥械通」政策支持，先行獲批引入大灣區，並完成首批處方落地，縮短了中國白癜風患者使用創新藥的用藥時差，讓更多國內白癜風患者獲益。展望未來，康哲藥業將繼續為滿足中國患者未盡之需而奮進，持續挖掘國際品質的新藥、好藥，高效推動產品臨床開發和商業化發展，以差異化的創新突破為病患帶來更多優質的醫藥產品，為守護患者健康生活和生命質量貢獻力量。關於蘆可替尼乳膏蘆可替尼乳膏（Opzelura），為Incyte的JAK1/JAK2選擇性抑制劑蘆可替尼的創新乳膏製劑，已獲得美國食品和藥物管理局（FDA）批準用於12歲及以上非節段型白癜風患者的局部治療。截至目前，蘆可替尼乳膏是首個也是唯一一種在美國獲批使用的白癜風複色產品[1]。此外，產品在美國獲批用於傳統外用處方療法不可取或不能充分控制病情之12歲及以上非免疫功能低下的輕中度AD患者的局部短期和非持續性慢性治療[2]。產品也於歐洲獲批用於12歲及以上青少年及成人患者伴面部受累的非節段型白癜風的治療[3]。康哲藥業於2022年12月2日，通過其附屬公司-康哲美麗與Incyte就用於治療自身免疫性炎症皮膚病的蘆可替尼乳膏製劑訂立合作和許可協議（「許可協議」）。根據該等許可協議，康哲藥業通過康哲美麗獲得在中國大陸、香港特別行政區、澳門特別行政區、台灣地區及東南亞十一國（印尼、菲律賓、越南、泰國、緬甸、馬來西亞、柬埔寨、老撾、新加坡、東帝汶以及文萊）（「區域」）開發、註冊及商業化產品的獨家許可權利，以及在區域內生產產品的非獨家許可權利。許可協議期限開始於許可協議生效日，自產品在區域內首次商業化銷售之日起擁有十年的授權期限（「授權期限」）。授權期限屆滿後，根據許可協議約定的特定條件，許可協議期限可延長十年（「初始延展授權期限」）。初始延展授權期限屆滿後，根據許可協議約定的特定條件，雙方可另行協商許可協議的延長期限。Incyte擁有產品的全球開發和商業化權利，產品在美國及歐洲以Opzelura®的名稱銷售。Opzelura及其logo為Incyte的注冊商標。關於白癜風白癜風是一種慢性自身免疫性疾病，其特徵是皮膚色素脫失，其發病原因為產生色素的細胞即黑素細胞的缺失。據估算，中國白癜風患者約1,400萬[4]。白癜風患者中約85%為非節段型白癜風。外用皮質類固醇（TCS）及鈣調神經磷酸酶抑制劑（CI）均為非節段型白癜風的標籤外用藥，然而，這些現有外用藥物療法有長期用藥的不良反應或療效有限的臨床痛點[5、6]。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化，把控產品全生命週期管理的開放式平台型企業，致力於提供有競爭力的產品和服務，滿足尚未滿足的醫療需求。康哲藥業專注於全球首創（FIC）及同類最優（BIC）的創新產品，並高效推進創新產品臨床研究開發和商業化進程，賦能科研成果向診療實踐的持續轉化，造福患者。康哲藥業聚焦專科領域，擁有被驗證的商業化能力，廣泛的渠道覆蓋和多疾病領域專家資源，核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展，以鞏固心腦血管/消化業務競爭力，並將皮膚醫美、眼科業務獨立運營，培育專科小領域的大龍頭，提升專科規模效率。同時業務版圖拓展至東南亞市場，著力成為全球藥企進軍東南亞市場的「橋頭堡」，助力康哲藥業高品質持續健康發展。參考文獻/資料：1、FDA批準信息可在FDA官網查詢，網址：https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2、FDA批準信息可在incyte官網查詢，網址：https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3、EMA批準信息可在EMA官網查詢，網址：https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4、Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75、《白癜風診療共識（2021版）》6、Kubelis-Lopez DE, Zapata-Salazar NA, Said-Fernandez SL, Sanchez-Dominguez CN, Salinas-Santander MA, Martinez-Rodriguez HG, Vazquez-Martinez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣，非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息，請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請，不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制，但康哲藥業並無進行任何說明或保證、明述或暗示，或其他表述，對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述，該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證，存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測，康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2024 亞太商訊 via SeaPRwire.com.

SHENZHEN, CHINA, Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product’s new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel treatment option for patients with relevant indication into designated medical institutions in the Mainland of Greater Bay Area.In addition, on 24 September, the NDA for vitiligo indication of ruxolitinib cream has been accepted by the National Medical Products Administration of China (NMPA). In accordance with the relevant regulations of the drug real-world data application pilot program in the Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Pilot Zone”), CMS has conducted a real-world study on ruxolitinib cream in China. The results have shown positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. All secondary efficacy endpoints showed a trend of benefit consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with longer treatment duration. Meanwhile, through the safety monitoring data of the Pilot Zone, no new safety events have been identified. Adverse events mostly had severity levels of grade 1 or 2. No adverse event (AE) leading to discontinuation or withdrawal, and no serious adverse event (SAE) related to the study drug occurred.If the Product is successfully approved for marketing in Mainland China, it will be the first prescription drug approved by NMPA for repigmentation in vitiligo, bringing this novel treatment hopes for Chinese vitiligo patients.Furthermore, on 12 August 2023, the Product was approved by Hainan Medical Products Administration for Urgent Clinical Import, and officially became available to applicable patients in the Pilot Zone on August 18, for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above with facial involvement. Benefiting from the Early and Pilot Implementation Policy granted by the state to Hainan Free Trade Port and the Pilot Zone, patients with vitiligo in China can apply for the Product in Boao Super Hospital first and receive treatment from the expert team. As of 30 June 2024, more than 3,200 patients have been treated with ruxolitinib cream in Boao Super Hospital.CMS has always been patient-oriented and innovation-driven based on clinical needs, continuously striving to improve drug accessibility. Benefited from the "Hong Kong and Macau Medicine and Equipment Connect" policy, ruxolitinib cream was approved for use in the Greater Bay Area and completed its first batch of prescriptions, shortening the time difference for Chinese vitiligo patients to use innovative drug and benefiting more domestic patients. Looking forward to the future, the Group will continuously strive to meet the unmet needs of Chinese patients, continuously explore novel drugs with international quality, and efficiently promote products’ clinical development and commercialization, so as to bring more quality pharmaceutical products through differentiated innovation-breakthrough, to safeguard the health and life-quality of patients.About ruxolitinib creamRuxolitinib cream (Opzelura), a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. As of now, it is the first and only treatment for repigmentation approved for use in the United States[1]. Ruxolitinib cream (Opzelura) is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable[2]. In Europe, ruxolitinib cream (Opzelura) is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].On 2 December 2022, the Group through a subsidiary of the Company, a dermatology medical aesthetic company (“CMS Skinhealth”) entered into a Collaboration and License Agreement (the “License Agreement”) with Incyte for topical formulations of ruxolitinib for the treatment of autoimmune and inflammatory dermatology diseases. In accordance with the License Agreement, the Group through CMS Skinhealth received an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (Indonesia, Philippines, Vietnam, Thailand, Myanmar, Malaysia, Cambodia, Laos, Singapore, Timor-Leste and Brunei Darussalam) (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The License Agreement commenced on its effective date and has a royalty term of ten years from the date of the commercial sale of the Product in the Territory (the “Royalty Term”). Upon the expiration of the Royalty Term, the License Agreement may be renewed for a period of ten years thereafter (the “Initial Extended Royalty Term”) as per certain conditions defined in the License Agreement. Upon the expiration of the Initial Extended Royalty Term, the License Agreement may be extended for a period otherwise agreed by both sides as per certain conditions defined in the License Agreement.Incyte has worldwide rights for the development and commercialization of the Product, marketed in the United States and Europe as Opzelura®. Opzelura and the Opzelura logo are registered trademarks of Incyte.About vitiligoVitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 14 million vitiligo patients in China[4]. Non-segmental vitiligo patients account for approximately 85% of them. Topical corticosteroids (TCS) and calcineurin inhibitors (CI) are used off-label for non-segmental vitiligo, however, these therapies have clinical deficiencies with long-term adverse reactions of long-term treatment or limited efficacy[5,6].About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries. While strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology business, CMS independently operates its dermatology and medical aesthetics business, and ophthalmology business, aiming to gain leading positions in specialty therapeutic fields, whilst enhancing the scale and efficiency. At the same time, CMS has expanded its business territory to the Southeast Asian market, striving to become a "bridgehead" for global pharmaceutical companies to enter the Southeast Asian market, further escorting the sustainable and healthy development of the Group.Reference:1. Drug approval information can be found on the FDA official website, as follows: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-addressing-repigmentation-vitiligo-patients-aged-12-and-older2. Drug approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream3. Drug approval information can be found on the EMA official website, as follows: https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura4. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74-84. doi:10.1016/S0140-6736(14)60763-75. Consensus on the diagnosis and treatment of vitiligo (2021 version)6. Kubelis-López DE, Zapata-Salazar NA, Said-Fernández SL, Sánchez-Domínguez CN, Salinas-Santander MA, Martínez-Rodríguez HG, Vázquez-Martínez OT, Wollina U, Lotti T, Ocampo-Candiani J. Updates and new medical treatments for vitiligo (Review). Exp Ther Med. 2021 Aug;22(2):797. doi: 10.3892/etm.2021.10229. Epub 2021 May 25. PMID: 34093753; PMCID: PMC8170669.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactChina Medical System Holdings Ltd.CMS Investor RelationsWebsite: https://web.cms.net.cn/en/home/Source: China Medical System Holdings Ltd. Copyright 2024 ACN Newswire via SeaPRwire.com.

Washington, D.C., Oct 18, 2024 - (ACN Newswire via SeaPRwire.com) - Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces.Multilateralism Index 2024 ReportAn image of the front cover of the Multilateralism Index 2024 ReportKey resultsThe performance of the multilateral system declined across all five domains examined.Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022.Climate action and human rights also saw significant declines in performance, despite increased engagement from member states.Participation in multilateral institutions has increased in most domains, even as performance has declined, indicating a shift from cooperation to contestation.Inclusivity improved across all domains, with steady growth in NGO engagement and women's representation in UN bodies.The Multilateralism Index 2024 presents a complex picture of global cooperation over the past decade, examining five crucial domains: Peace and Security, Human Rights, Climate Action, Public Health, and Trade. It reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined.Dr. Adam Lupel, IPI Vice President & COO said: "Over the past decade, we've witnessed a paradox in multilateralism. While participation in international institutions has largely held steady or even increased, the performance of the multilateral system in addressing global challenges has declined. This suggests a shift from cooperation to contestation at a time of transformation and rising global crises."The peace and security domain experienced the most significant deterioration in performance. Active armed conflicts increased from 39 in 2013 to 55 in 2022, with a notable rise in internationalized conflicts. The UN Security Council has seen more frequent use of the veto power, constraining its ability to respond to crises. However, states have not broadly pulled back from the UN peace and security architecture, and commitments in some areas, such as multilateral peacebuilding, have increased.Climate action presents another contradiction. Despite near-universal participation in the Paris Agreement and growing climate commitments, these commitments continue to fall short of necessary targets. Projections show an 8.8% increase in emissions by 2030, in stark contrast to the 43% decrease required to meet the critical 1.5°C target.The human rights domain exhibits a counterintuitive pattern. While engagement with UN human rights mechanisms has increased, global human rights protections have steadily declined. Most strikingly, members of the UN Human Rights Council consistently scored lower on human rights measures than the global average, indicating that many states are engaging less to advance human rights than to shape the direction of the system.Multilateral action on public health was significantly shaped by the COVID-19 pandemic, which reversed years of progress, particularly in areas such as childhood immunization. It also put the shortcomings of the global public health system in stark relief, spurring negotiations on an international pandemic agreement aimed at strengthening preparedness and response capabilities for future health crises.Trade is the one area where both performance and participation decreased. The paralysis of global trade negotiations and breakdown in adherence to global trade rules signal a shift away from multilateral approaches. This trend, combined with growing geopolitical tensions, creates challenges for global economic cooperation.Steve Killelea, Founder & Executive Chairman of IEP, commented: "The Multilateralism Index 2024 reveals a challenging trend: while engagement in global institutions has increased, their effectiveness has declined across key areas. There is a need to revitalize our multilateral system to address today's complex challenges."Despite these challenges, the Index highlights positive developments, particularly in the area of inclusivity. NGO engagement with the UN system has grown, and women's representation has increased across many UN bodies. However, the Global South remains underrepresented in many areas, suggesting that geographic inclusivity remains a work in progress.As the world contends with interconnected crises, from conflict to climate change, the Multilateralism Index 2024 provides valuable insights into the current state of global cooperation. It underscores the need for thoughtful reform to ensure that multilateral institutions can effectively address the complex challenges of the 21st century.Contact InformationMike KoslowskiIEP Senior Communications Advisormkoslowski@economicsandpeace.org+61418410531Related FilesMultilateralism Index 2024 - Full Press Release (1)Multilateralism Index 2024 - Full Press Release (1)SOURCE: International Peace Institute Copyright 2024 ACN Newswire via SeaPRwire.com.

香港, 2024年10月17日 - (亞太商訊 via SeaPRwire.com) - 國泰君安國際控股有限公司（「國泰君安國際」、「公司」或「集團」，股份代號：1788.HK）欣然宣佈，公司連續第六年參與由香港勞工處推出的《好僱主約章》計劃，致力於採取良好的人事管理措施，並為員工營造家庭友善的工作環境。《好僱主約章》2024以「為你『家』『友』好僱主」為主題，鼓勵各行業及不同規模的僱主推行及優化以僱員為本的家庭友善僱佣措施，將心比己體諒僱員兼顧工作及家庭的責任，締造家庭友善的工作環境。此次簽署《好僱主約章》，展現了公司在員工關懷及營造和諧共融工作環境方面所做出的努力。國泰君安國際一直關愛員工，秉承「人才是第一資源」的經營理念，奉行「以人為本，協同協作」的人才理念，視員工為企業的核心資產，打造包容、健康的工作環境，並提供充足的資源支持員工的成長與發展。未來，國泰君安國際將繼續致力於提升員工滿意度，營造一個更加友善和諧的工作環境，為締造和諧共融的社會貢獻力量。 Copyright 2024 亞太商訊 via SeaPRwire.com.

San Francisco, CA & Hanoi, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - VPBank, one of Vietnam’s largest private banks, partners with CleverTap, the all-in-one customer engagement platform, to deepen understanding of customers and their aspirations and use the insights to deliver hyper-personalized experiences to users, at scale. VPBank aims to elevate customer experience and drive higher conversions on products and offers through highly targeted campaigns built on complex, real-time segmentation that quickly connects with customers. Through this association with CleverTap, VPBank’s objective is to improve engagement, deepen relationships and drive higher retention, while keeping costs low.Established in 1993, VPBank operates in a wide variety of businesses including retail banking, corporate banking, wealth management, and consumer finance. VPBank aims to become a top-ranking financial institution among joint stock commercial banks in Vietnam, in terms of business scale, market share, and service quality. Leveraging CleverTap’s AI/ML-powered capability suite, Clever.AI, VPBank will be able to hyper-personalize its engagement via multiple automation and journeys. It will enable a seamless and omnichannel onboarding experience for new users, driving higher success rates for key milestones such as registration and the first transaction. With the unified customer view on CleverTap, VPBank can identify high-intent users and target them with contextual and relevant offerings, achieving an increase in customer lifetime value.Varun Krishna, Head of Digital Marketing, VPBank said, “We’ve always strived to maintain our position as one of Vietnam’s leading financial institutions. In an increasingly competitive banking landscape, delivering personalized and meaningful customer experiences is paramount. Partnering with CleverTap empowers us to harness advanced AI-driven insights, enabling us to engage our customers more effectively and tailor our offerings to their unique needs across digital channels. This collaboration not only enhances our ability to connect with customers on a deeper level but also drives sustained growth and loyalty. Together, we are committed to setting new standards in customer engagement and positioning VPBank as the most trusted and preferred bank in Vietnam.”Mai Vo, Country Manager, CleverTap said, “Vietnam’s banking sector is at the precipice of a new era of growth. Our partnership with VPBank couldn’t be timed better. With a legacy of innovation and customer-centricity, VPBank has consistently set benchmarks in the Vietnamese banking industry. Their commitment to using technology for crafting exceptional customer experiences aligns perfectly with our vision. Together, with CleverTap’s state-of-the-art omnichannel platform, personalizing and enhancing customer engagement has never been more seamless. This partnership is not only a testament to CleverTap’s expertise in driving conversion and retention but also underscores VPBank’s leadership in propelling Vietnam's banking sector into a new era of excellence”About CleverTapCleverTap is the leading all-in-one customer engagement platform that helps brands unlock limitless customer lifetime value. CleverTap is trusted by over 2000 brands like Domino’s, Levis, Jio, Papa John’s, Zomato, Kotak Bank, Air Asia, Carousell, TD Bank, and Tesco to help build personalized experiences for all their customers. The platform is powered by TesseractDB™ – the world’s first purpose-built database for customer engagement, offering speed and cost efficiency at scale.Backed by top-tier investors such as Accel, Peak XV Partners, Tiger Global, CDPQ and 360 One, the company is headquartered in San Francisco, with presence across Seattle, London, São Paulo, Bogota, Mexico, Amsterdam, Sofia, Dubai, Mumbai, Bangalore, Singapore, Vietnam, and Jakarta.For more information, visit clevertap.com or follow us on:LinkedIn: https://www.linkedin.com/company/clevertap/ X: https://twitter.com/CleverTap Forward-Looking StatementsSome of the statements in this press release may represent CleverTap's belief in connection with future events and may be forward-looking statements, or statements of future expectations based on currently available information. CleverTap cautions that such statements are naturally subject to risks and uncertainties that could result in the actual outcome being absolutely different from the results anticipated by the statements mentioned in the press release.Factors such as the development of general economic conditions affecting our business, future market conditions, our ability to maintain cost advantages, uncertainty with respect to earnings, corporate actions, client concentration, reduced demand, liability or damages in our service contracts, unusual catastrophic loss events, war, political instability, changes in government policies or laws, legal restrictions impacting our business, impact of pandemic, epidemic, any natural calamity and other factors that are naturally beyond our control, changes in the capital markets and other circumstances may cause the actual events or results to be materially different, from those anticipated by such statements. CleverTap does not make any representation or warranty, express or implied, as to the accuracy, completeness, or updated or revised status of such statements. Therefore, in no case whatsoever will CleverTap and its affiliate companies be liable to anyone for any decision made or action taken in conjunction.For more information:SONY SHETTYDirector, Communications, CleverTap+91 9820900036sony@clevertap.com ASHMIT CHAUDHARYAssociate Consultant, Archetype+91 8850752121ashmit.chaudhary@archetype.co Copyright 2024 ACN Newswire via SeaPRwire.com.

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activitiesNo serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos’ Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063LOS ANGELES, CA, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of inflammatory bowel disease (IBD).The clinical trial was a randomized, double-blind, placebo-controlled study in healthy volunteers designed to evaluate safety and PK as well as provide pharmacodynamic (PD) data to provide confirmation of ATH-063's proposed mechanism of action. The trial was conducted as sequential single ascending dose (SAD) (n=32) and multiple ascending dose (MAD) (n=32) arms, and a separate food-effect (FE) (n=12) arm. Four doses (25, 75, 150, and 250 mg) of ATH-063 were administered orally.PD data showed ATH-063 selective expansion and activation of Tregs, consistent with predictions made by Athos' AI2 platform:Statistically significant increases (p

- The two major electronics fairs concluded today, attracting over 60,000 industry buyers from 136 countries and regions- 53% of respondents in an on-site survey expect overall sales to increase over the next 12-24 months, while 43% expect sales to remain stable- Most respondents believe there is a “very promising” or “promising” market potential for wearable electronic products (65%) and robotics technology (59%)HONG KONG, Oct 16, 2024 - (ACN Newswire via SeaPRwire.com) - The Hong Kong Electronics Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), and electronicAsia, jointly organised by the HKTDC and MMI Asia Pte Ltd, concluded their physical exhibitions today.The four-day events attracted more than 60,000 industry buyers from 136 countries and regions. The number of buyers from Malaysia, Türkiye, Argentina and the UAE increased from last year. This reflects the exhibitions' status as important sourcing platforms for the industry.Sophia Chong, Deputy Executive Director of the HKTDC, said: "The global trend towards smart living is driving demand for innovative products and solutions. The Electronics Fair and electronicAsia serve as efficient platforms for the industry, enabling exhibitors to showcase their electronic products and technology solutions to buyers. We are pleased to see exhibitors and buyers successfully exploring business opportunities at the exhibitions, which are expediting Hong Kong's development into an international innovation and technology (I&T) centre.”In late October, the HKTDC will host the Hong Kong International Lighting Fair (Autumn Edition), Hong Kong International Outdoor and Tech Light Expo and ECO Expo Asia to create more cross-industry business opportunities.Industry optimistic about India, the Middle East, Latin AmericaAn independent survey agency commissioned by the HKTDC interviewed 1,091 Electronics Fair buyers and exhibitors about growth prospects for the industry. 53% of respondents expect overall sales to increase in the next 12-24 months, while 43% anticipate that they will remain stable. Most respondents believe that the electronics industry has the most growth potential in emerging markets, such as India, the Middle East and Latin America over the next two years, followed by Korea, Mainland China, Australia and the Pacific Islands.In terms of trends in electronic products, most respondents believe there is a “very promising” or “promising” market potential for wearable electronic products (65%) and robotics technology (59%).Meanwhile, 56% of respondents believe that the market potential for e-sports products and equipment is high. Most respondents consider these products to have the greatest growth potential in North America and Northern and Western Europe.Exhibitors attract quality buyers at fairsThis year's Electronics Fair featured more than 20 zones, gathering the latest electronic products and innovative solutions from global exhibitors in areas such as smart cities, smart mobility, gerontechnology and digital entertainment.First-time exhibitor and Founder of Zunosaki Limited, Newmen Ho, promoted the company's hand rehabilitation robot in the Startup Zone, seeking Mainland China and overseas distributors, partners and investors. In the first half of the exhibition, he met potential buyers from Taiwan’s nursing homes and from Korea. Additionally, a buyer from India expressed interest in applying the company's robotic hand technology across different industries.Hong Kong's renowned consumer electronics brand Momax achieved impressive results at the fair. The company's Founder and CEO John Cheng stated that in the first two days of the Fair, the team met some 60 buyers from the Asia-Pacific region and Europe. Momax also formed a long-term partnership with a publicly listed company in Papua New Guinea and is currently discussing an initial order valued at US$50,000.Additionally, through HKTDC’s Click2Match smart business matching platform, the company connected with another quality buyer from Australia, with the intent to collaborate long-term. Mr Cheng said: "Hong Kong's exhibitions are world-class, featuring high-quality buyers from a diverse range of countries. This year's Autumn Electronics Fair saw a significant turnout, and the buyers were very engaged. We will definitely participate again next year."Dongguan Maochang Printed Circuit Board Ltd, which develops technological solutions, participated in electronicAsia to stay updated on industry trends and identify potential buyers. The company's Sales Director, Michael Tsang, said: "Expanding onto the international stage is our primary goal for participating in the exhibition. I am glad that we met with over 200 potential buyers in the first three days to gain a deeper understanding of customer needs."Buyer seeks new products to expand marketVinal Patel, Chief Commercial Officer of UK buyer Brand Collective, has been attending the Electronics Fair for over 20 years. During the first two days of this year's fair, he secured over US$2 million worth of purchases, including charging cables, power banks and wireless speakers from two exhibitors. He is also considering expanding the range of products he distributes after discovering new offerings at the Fair. Mr Patel said: "The line-up at the exhibition gets better every year, even more impressive than before the pandemic. I will definitely participate in the Electronics Fairs in April and October in the future."Turkish buyer and Co-founder of Robotistan Elektronik Tic AS, Yusuf Gündogdu, visited electronicAsia with a purchasing budget of around U$100,000-200,000 for electronic products. He said: "The Electronics Fair is the best opportunity for me to interact face-to-face with exhibitors from around the world. I always find the best prices here. Meeting the founders of start-ups in the Startup Zone excites me. These companies are poised to become some of the best in the future and will drive market development through innovation, which I eagerly look forward to."The organisers held 78 events and forums during the exhibitions, inviting industry leaders to share unique insights and the latest industry information. These events included the Symposium on Innovation & Technology, Hong Kong Electronic Forum and Reliability Assurance for Electronic Systems Forum. Other on-site activities catered to start-ups, including investment matching, the Hong Kong Value Creation for Technology: Pitching Competition, Meet the Mentors sessions and Start-up Smart Launch.Under the EXHIBITION+ hybrid model, exhibitors and buyers can use the Click2Match smart business matching platform to conduct online meetings, in addition to attending the physical fair. Exhibitors and buyers can still explore business opportunities and conduct online negotiations through Click2Match until 23 October.Photo Download:https://bit.ly/3BVmX2RHong Kong Electronics Fair (Autumn Edition) and electronicAsia successfully concluded. The four-day events attracted over 60,000 buyers from 136 countries and regionsThis year's Symposium on Innovation & Technology, themed 'When Two Worlds Collide: The Confluence of Digital Twins & Real-Life Applications', featured heavyweight guests and attracted numerous industry professionalsThe Hall of Fame gathered consumer electronic products from renowned brands worldwide. Among them, Asia Kingston (HK) Limited, specialising in brand licensing, presented a gaming chair featuring the NASA logoLocal brands, including well-known electronic brand Momax, promoted their products to global buyersThe Tech Hall showcased products using a variety of cutting-edge technologies, including 3D printing, Internet of Things, robotics, AR and XRThis year's Electronics Fair introduced a Digital Entertainment Experience Zone, where buyers could try and explore products on-siteThe concurrent electronicAsia featured multiple zones, exhibiting products, such as electronic components and parts, keyboards and switches, power supply equipment and moreThe Hong Kong Electronic Forum, co-organised by the HKTDC, MMI Asia Pte Ltd and the Hong Kong Electronic Industries Association, was themed “Innovation Unleashed: The Intersection of Microelectronics, AI, and Open-Source Ecosystems”WebsitesHong Kong Electronics Fair (Autumn Edition): hkelectronicsfairae/enelectronicAsia: electronicasia/enMedia enquiriesPlease contact the HKTDC’s Communications & Public Affairs Department:Katy WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgSnowy ChanTel: (852) 2584 4525Email: snowy.sn.chan@hktdc.orgHKTDC Media Room: https://mediaroom.hktdc.com/enAbout the HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong ’s trade. With 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly SMEs, in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via trade publications, research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2024 ACN Newswire via SeaPRwire.com.

HONG KONG, Oct 17, 2024 - (ACN Newswire via SeaPRwire.com) - Guotai Junan International Holdings Limited (“Guotai Junan International”, “GTJAI”, the “Company” or the “Group”, stock code: 1788.HK) is pleased to announce that the Company has participated in the Good Employer Charter Scheme launched by the Hong Kong Labour Department for the sixth consecutive year, committed to adopting good personnel management practices and creating a family-friendly working environment for employees.The Good Employer Charter 2024 features the theme of “Supportive Family-friendly Good Employer”. Employers of different industries and scales are encouraged to adopt and enhance employee-oriented family-friendly employment practices, putting themselves in the employees’ shoes in discharging both work and family obligations, so as to create a family-friendly working environment. This signing of the Good Employer Charter demonstrates the Company’s efforts in employee care and creating a harmonious and inclusive working environment.GTJAI has always cared for its employees. Adhering to the business philosophy of “Talent as the First Resource” and pursuing the talent concept of “People-oriented, Collaborative Cooperation”, GTJAI considers employees as its core asset and has always been devoted to creating an inclusive and healthy working environment, and providing adequate resources to support employees’ growth and development. In the future, GTJAI will continue to strive to improve employee satisfaction, create a more friendly working environment, and contribute to building a harmonious and inclusive society. Copyright 2024 ACN Newswire via SeaPRwire.com.